
    
      This is a Phase II, open-label pilot study to determine if the use of Rituximab reduces
      proteinuria over a 12 month period and is there preservation of kidney function with the use
      of this study drug. Each patient will be treated with 2 intravenous infusions of rituximab
      1000 mg, two weeks apart for a total of 2 doses. Each patient will be retreated with
      identical 2 intravenous infusions of rituximab, two weeks apart at 6 months after the first
      infusion, irrespective of cluster of differentiation (CD) 20+ cell counts. Thus, each
      participant will receive 4 infusions of rituximab.
    
  